L.E.K.’s Take on China Medtech: Optimistic Macro View, Short-Term Hit Hard Stephen Sunderland Read more
Related Practice MedTech Despite the COVID-19 lockdown, Stephen Sunderland foresees limited disruption 07102020100744
Executive Insights Organization & Performance Cost-Cutting Strategies To Mitigate the Impact of Inflation July 12, 2023
Special Report Digital Digital Excellence in Healthcare and Life Sciences: Riding the Wave of Innovation March 30, 2023
Executive Insights Life Sciences & Pharma Clinical Trial Challenges: Patient Recruitment and Diversity March 11, 2023
Executive Insights Life Sciences & Pharma L.E.K. Consulting’s Look at Key Trends in Pharma Services for 2023 March 2, 2023
Executive Insights Biotech and Pharmaceuticals Shareholder Value Creation for First-Time Launchers: Two Decades of Learnings December 30, 2022
